BioTherapeutics

Beyond's analysis on BioTherapeutics

• 2026-09-08 — Protalix BioTherapeutics schedules investor presentations for September 2026 to engage with the financial community

Recent news mentioning BioTherapeutics

• 2026-10-02 — Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
• 2026-10-01 — Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
• 2026-10-01 — Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
• 2026-10-01 — Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
• 2026-09-28 — Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
• 2026-09-25 — Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
• 2026-09-25 — Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference
• 2026-09-24 — Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
• 2026-09-23 — Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
• 2026-09-21 — Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
• 2026-09-21 — Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig
• 2026-09-18 — Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Browse the full archive →